Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial

Genetics in Medicine

Volumn 6, Issue 4, 2004, Pages 197-203

  Roberts, J Scott ^a   Barber, Melissa ^b   Brown, Tamsen M ^a   Cupples, L Adrienne ^c   Farrer, Lindsay A ^a,c   LaRusse, Susan A ^d   Post, Stephen G ^e   Quaid, Kimberly A ^f   Ravdin, Lisa D ^g   Relkin, Norman R ^g   Sadovnick, A Dessa ^h   Whitehouse, Peter J ^b   Woodard, John L ⁱ   Green, Robert C ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Alzheimer's disease; APOE; Genetic counseling; Genetic testing; Test uptake

Indexed keywords

APOLIPOPROTEIN E;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED;

EID: 3442890962     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000132688.55591.77     Document Type: Article

References (35)

1. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389.
2. Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003;35:131-138.
3. Masters CL, Beyreuther K. Science, medicine, and the future: Alzheimer's disease. BMJ 1998;316:446-448.
4. Roses AD. Genetic testing for Alzheimer disease: practical and ethical issues. Arch Neurol 1997;54:1226-1229.
5. Blacker D, Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 1998;55:294-296.
6. St. George-Hyslop PH, Farrer LA, Goedert M. Alzheimer disease and the fronto-temporal dementias: diseases with cerebral deposition of fibrillar proteins. In: Scriver C et al., eds. Molecular and metabolic basis of inherited disease, 8th ed. Columbus, OH: McGraw-Hill, 2000:4:5785-5899.
7. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: A meta-analysis. JAMA 1997;278:1349-1356.
8. Karlinsky H, Sadovnick AD, Burgess MM, Lnglois S, Hayden MR, Berg JM. Issues in molecular genetic testing of individuals with suspected early-onset familial Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:116-125.
9. Green RC. Genetic testing for Alzheimer's disease: has the moment arrived? Alz Care Quarterly 2002;208-214.
10. Brodaty H, Conneally M, Gauthier S, Jennings C, Lennox A, Lovestone S. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9:182-187.
11. Farrer LA, Brin MF, Elsas L et al. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-1629.
12. Relkin NR, National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-1095.
13. Post SG, Whitehouse PJ, Binstock RH et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997;277:832-836.
14. McConnell LM, Koenig BA, Greely HT, Raffin TA, and the Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics, & Society. Genetic testing and Alzheimer disease: has the time come? Nat Med 1998:4:757-759.
15. Roberts JS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist 2000;40:43-52.
16. Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R. Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Dis Assoc Disord 1997;11(suppl 5):S1-S5.
17. Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test 2003;7:39-44.
18. Neumann PJ, Hammitt JK, Mueller C et al. Public attitudes about genetic testing for Alzheimer's disease. Health Aff 2001;20:252-264.
19. Quaid KA, Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 1993;45:41-45.
20. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status - Standardization Edition Manual. San Antonio, TX: The Psychological Corporation, 1995.
21. Radloff LS. The CES-D Scale: A self report depression scale for research in the general population. Appl Psychol Measur 1977;1:385-401.
22. Beck AT, Steer RA. Beck Depression Inventory. New York: The Psychological Corporation, Harcourt Brace Javanovich, Inc.; 1987.
23. Cupples LA, Farrer LA, Sadovnick AD et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: The REVEAL Study. Genet Med 2004;6:000-000.
24. Green RC, Cupples LA, Go R et al. Risk of dementia among white and African American relatives of Alzheimer's disease patients. JAMA 2002;287:329-336.
25. Lautenschlager NT, Cupples LA, Rao VS et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 1996;46:641-650.
26. Craufurd D, Kerzin-Storrer L, Dodge A, Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 1989:603-605.
27. Tambor ES, Bernhardt BA, Chase GA et al. Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet 1994;55:626-637.
28. Codori AM, Petersen GM, Miglioretti DL et al. Attitudes toward colon cancer gene testing: factors predicting test uptake. Cancer Epidemiol Biomarkers Prev 1999;8:345-351.
29. Lerman C, Narod S, Schulman K et al. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 1996;275:1885-1892.
30. Evans D, Gareth R, Maher ER et al. Uptake of genetic testing for cancer predisposition. J Med Genet 1997;34:746-748.
31. Meiser B, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry 2000;69:574-578.
32. Roberts JS, LaRusse SA, Katzen H et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:86-93.
33. Brown TC, Roberts JS, LaRusse SA et al. Impact of genetic risk assessment for Alzheimer disease. J Genet Counseling 2002;11:446-447.
34. Roberts JS, Green RC, Relkin NR et al. How do participants rate the impact of genetic susceptibility testing for Alzheimer's disease? Neurology 2003;60:A453.
35. Marteau TM, Croyle RT. The new genetics: Psychological responses to genetic testing. BMJ 1998;316:693-696.